FrancophonIA/ELRC3.0 huggingface dataset:
English: One of the studies also looked at the effects of Duavive on osteoporosis; however, as there was no benefit of Duavive over the individual components the company withdrew its application for Duavive in the treatment of osteoporosis.
Estonian: Ühes uuringus vaadeldi Duavive toimet osteoporoosile; et aga Duavive ei olnud kasulikum kui selle koostisosad eraldi, võttis ettevõte tagasi taotluse Duavive kasutamise kohta osteoporoosi raviks.
English: Duavive conjugated oestrogens / bazedoxifene
Estonian: Duavive konjugeeritud östrogeenid / basedoksifeen
English: This is a summary of the European public assessment report (EPAR) for Duavive.
Estonian: See on ravimi Duavive Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP also noted that long-term use of Duavive is associated with a risk of stroke and venous thromboembolism which is similar to the risk with conjugated oestrogens and bazedoxifene when used alone.
Estonian: Veel märkis inimravimite komitee, et Duavive pikaajaline kasutamine on seotud insuldi ja veeni tromboemboolia riskiga, mis on sarnane kas ainult konjugeeritud östrogeenide või basedoksifeeni kasutamise riskiga.
English: Duavive therefore also contains the active substance bazedoxifene, which blocks the effects of oestrogens on the womb and so reduces the risk of endometrial cancer.
Estonian: Seepärast sisaldab Duavive ka toimeainet basedoksifeen, mis blokeerib östrogeenide toime emakale ja vähendab seega endomeetriumi vähi riski.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Duavive, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Duavive omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Duavive was compared with placebo (a dummy treatment) in two main studies in 996 women who have been through the menopause, investigating the effects on either hot flushes or vulvovaginal atrophy (dryness, irritation and soreness around the genital area).
Estonian: Duavivet võrreldi platseeboga (näiv ravim) kahes põhiuuringus, milles osales 996 menopausijärgses eas naist, kellel uuriti toimet kas kuumahoogudele või vulvovaginaalsele atroofiale (kuivus, ärritus ja valulikkus suguelundite piirkonnas).
English: However, oestrogens used alone can cause hyperplasia (growth) of the endometrium (lining of the womb) which could lead to endometrial cancer.
Estonian: Östrogeenide kasutamisel ainsa ravimina võib aga tekkida endomeetriumi (emaka limaskest) hüperplaasia (kasv), mis võib põhjustada endomeetriumi vähki.
English: For practical information about using Duavive, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Duavive kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For the full list of all side effects and restrictions with Duavive, see the package leaflet.
Estonian: Duavive kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Duavive contains two active substances: conjugated oestrogens and bazedoxifene.
Estonian: Duavive sisaldab kaht toimeainet: konjugeeritud östrogeene ja basedoksifeeni.
English: Some women must not use Duavive including those who have had problems with venous thromboembolism (blood clots in the veins) such as deep-vein thrombosis (DVT), pulmonary embolism (a blood clot in the lungs) and retinal-vein thrombosis (a blood clot at the back of the eye), or are at an increased risk of such problems.
Estonian: Duavivet ei tohi kasutada mõned naised, sealhulgas need, kellel on olnud probleeme veeni tromboembooliaga (trombid veenides), näiteks süvaveenide tromboos, kopsuemboolia (tromb kopsus) ja võrkkesta veeni tromboos (tromb silma tagaosas), või kellel on selliste probleemide risk suurem.
English: Treatment with Duavive also led to a greater average fall in the daily severity score of hot flushes than placebo treatment: 0.9 versus 0.3.
Estonian: Samuti vähendas ravi Duavivega kuumahoogude igapäevast raskusastet keskmiselt rohkem kui ravi platseeboga: 0,9 võrreldes 0,3-ga.
English: It is available as modified release tablets (containing 0.45 mg conjugated oestrogens and 20 mg bazedoxifene) which release bazedoxifene immediately and conjugated oestrogens over a longer period of time.
Estonian: Seda turustatakse toimeainet modifitseeritult vabastavate tablettidena (mis sisaldavad 0,45 mg konjugeeritud östrogeene ja 20 mg basedoksifeeni), mis vabastavad basedoksifeeni kohe ja konjugeeritud östrogeene pikema aja jooksul.
English: Similar results were seen with a higher strength of conjugated oestrogen (0.625 mg) plus bazedoxifene 20 mg when compared with placebo.
Estonian: Sarnased tulemused saavutati suurema tugevusega konjugeeritud östrogeenide (0,625 mg) ja 20 mg basedoksifeeni võrdlemisel platseeboga.
English: In the study investigating the effects on hot flushes, treatment with Duavive (conjugated oestrogen 0.45 mg and bazedoxifene 20 mg) over 12 weeks reduced the average daily number of moderate and severe hot flushes by 7.6 compared with 4.9 for placebo.
Estonian: Uuringus, milles vaadeldi toimet kuumahoogudele, vähendas ravi Duavivega (0,45 mg konjugeeritud östrogeene ja 20 mg basedoksifeeni) 12 nädala jooksul mõõdukate ja raskete kuumahoogude keskmist arvu 7,6 võrra võrreldes 4,9-ga platseebo puhul.
English: For more information about treatment with Duavive, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Duavivega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Conjugated oestrogens have been available for many years as hormone replacement therapy and bazedoxifene has been authorised in 2009 for the treatment of osteoporosis (a disease that makes bones fragile) in women who have been through the menopause.
Estonian: Konjugeeritud östrogeene on turustatud mitu aastat hormoonasendusravina ja basedoksifeen kiideti 2009. aastal heaks osteoporoosi (luuurbnemus) raviks menopausijärgses eas naistel.
English: What benefits of Duavive have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Duavive kasulikkus?
English: Duavive is a medicine used for the treatment of symptoms (such as hot flushes) caused by low blood levels of the female hormone oestrogen in women who have been through the menopause.
Estonian: Duavive on ravim, mida kasutatakse selliste sümptomite (nt kuumahood) raviks, mida põhjustab naissuguhormooni östrogeen väike sisaldus veres menopausijärgses eas naistel.
English: One of the active substances in Duavive, conjugated oestrogens, works as hormone replacement therapy.
Estonian: Duavive üks toimeaine, konjugeeritud östrogeenid, toimib hormoonasendusravina.
English: How does Duavive work?
Estonian: Kuidas Duavive toimib?
English: The study looking at the effects of Duavive on vulvovaginal atrophy found an improvement in some of the signs of vaginal atrophy but not in the most bothersome symptoms when compared with placebo.
Estonian: Uuringus, milles vaadeldi Duavive toimet vulvovaginaalsele atroofiale, leiti, et võrreldes platseeboga vähenesid mõned vulvovaginaalse atroofia märgid, kuid mitte kõige tülikamad sümptomid.
English: Duavive is only for use in women who have been through the menopause, so it must not be used in women who could become pregnant.
Estonian: Duavivet tohib kasutada ainult menopausijärgses eas naistel, seda ei tohi kasutada fertiilses eas naistel.
English: Duavive can only be obtained with a prescription.
Estonian: Duavive on retseptiravim.
English: Duavive was shown to improve the symptoms caused by lack of oestrogen in postmenopausal women when compared with placebo.
Estonian: Platseeboga võrdlemisel tõendati, et Duavive leevendab menopausijärgses eas naiste östrogeenipuudusest tulenevaid sümptomeid.
English: Further information on NovoEight can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/novoeight.
Estonian: Lisateave NovoEighti kohta on ameti veebilehel: ema.europa.eu/en/medicines/human/EPAR/novoeight.
English: What measures are being taken to ensure the safe and effective use of NovoEight?
Estonian: Mis meetmed võetakse, et tagada NovoEighti ohutu ja efektiivne kasutamine?
English: The European Medicines Agency decided that NovoEight's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et NovoEighti kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: As for all medicines, data on the use of NovoEight are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse NovoEighti kasutamise kohta pidevat järelevalvet.
English: Patients or their carers may be able to inject NovoEight themselves once they have been trained.
Estonian: Patsiendid või nende hooldajad tohivad süstida NovoEighti ise, kui nad on saanud väljaõppe.
English: Other information about NovoEight
Estonian: Muu teave NovoEighti kohta
English: NovoEight received a marketing authorisation valid throughout the European Union on 13 November
Estonian: NovoEight on saanud müügiloa, mis kehtib kogu ELis, 13. novembril 2013.
English: Hypersensitivity (allergic) reactions can occur rarely with NovoEight and may in some cases progress to severe allergic reactions.
Estonian: NovoEighti kasutamisel võib harva esineda ülitundlikkusreaktsioone (allergiareaktsioone), mis võivad mõnel juhul progresseeruda rasketeks allergilisteks reaktsioonideks.
English: NovoEight (turoctocog alfa) EMA/655123/2019
Estonian: NovoEight (alfaturoktokog) EMA/655123/2019
English: NovoEight (turoctocog alfa)
Estonian: NovoEight (alfaturoktokog)
English: These inhibitors are antibodies that the immune system (the body's natural defences) produces against factor VIII.
Estonian: Need inhibiitorid on antikehad, mida immuunsüsteem (organismi looduslikud kaitsemehhanismid) toodab VIII hüübimisfaktori vastu.
English: Side effects reported with NovoEight are carefully evaluated and any necessary action taken to protect patients.
Estonian: NovoEighti kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: The dose and frequency of treatment depend on whether it is used to treat or prevent bleeding, as well as the seriousness of the haemophilia, the extent and location of the bleeding and the patient's age and condition.
Estonian: Ravi annus ja manustamissagedus sõltuvad sellest, kas ravimit kasutatakse verejooksu raviks või ennetamiseks, samuti hemofiilia raskusest, verejooksu raskusest ja kohast ning patsiendi vanusest ja seisundist.
English: In addition, 89.4% of the bleeding episodes resolved after 1 to 2 doses of NovoEight.
Estonian: Lisaks lahenes 89,4% verejooksuepisoodidest pärast 1-2 NovoEighti annust.
English: For more information about using NovoEight, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet NovoEighti kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: In the second study involving 63 children less than 12 years of age, children treated with NovoEight had an average of 5.33 bleeding episodes per year.
Estonian: Teises uuringus, milles osales 63 alla 12-aastast last, esines NovoEightiga ravitud lastel keskmiselt 5,33 verejooksuepisoodi aastas.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoEight have been included in the summary of product characteristics and the package leaflet.
Estonian: NovoEighti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What is NovoEight and what is it used for?
Estonian: Mis on NovoEight ja milleks seda kasutatakse?
English: NovoEight must not be used in patients who are allergic to hamster protein.
Estonian: NovoEighti ei tohi kasutada patsiendid, kes on allergilised hamstri valkude suhtes.
English: For continuing treatment, the doctor may adjust the dose and frequency of injection according to the blood levels of factor VIII.
Estonian: Ravi jätkamiseks võib arst kohandada annust ja süstimissagedust vastavalt VIII hüübimisfaktori sisaldusele veres.
English: In addition, 95.2% of the bleeding episodes resolved after 1 to 2 doses of NovoEight.
Estonian: Lisaks lahenes 95,2% verejooksuepisoodidest pärast 1-2 NovoEighti annust.
English: In the first study involving 150 patients aged 12 years and above, adolescents who used NovoEight to prevent bleeding had an average of 5.55 bleeding episodes per year and adults had an average of 6.68 bleeding episodes per year.
Estonian: Esimeses uuringus, milles osales 150 vähemalt 12-aastast patsienti, esines NovoEighti verejooksude ennetamiseks kasutanud noorukitel aastas keskmiselt 5,55 verejooksuepisoodi ja täiskasvanutel keskmiselt 6,68.
English: When used for the treatment of spontaneous bleeding, NovoEight was rated as ‘excellent' or ‘good' at treating 403 of 499 of the bleeding episodes.
Estonian: Spontaansete verejooksude ravis kasutamisel hinnati NovoEighti väga heaks või heaks 403 verejooksuepisoodi ravis 499st.
English: NovoEight is used to correct the factor VIII deficiency by replacing the missing factor VIII, thereby giving temporary control of the bleeding disorder.
Estonian: NovoEighti kasutatakse VIII hüübimisfaktori vaeguse korrigeerimiseks, asendades puuduva VIII hüübimisfaktori ja seega ajutiselt ohjates veritsushäiret.
English: How is NovoEight used?
Estonian: Kuidas NovoEighti kasutatakse?
English: What are the risks associated with NovoEight?
Estonian: Mis riskid NovoEightiga kaasnevad?
English: NovoEight was rated as ‘excellent' or ‘good' at treating 116 of the 126 bleeding episodes.
Estonian: NovoEighti hinnati väga heaks või heaks 116 verejooksuepisoodi ravis 126st.
English: The safety profile of NovoEight was also considered similar to other factor VIII products.
Estonian: Ka NovoEighti ohutusprofiili peeti sarnaseks teiste VIII hüübimisfaktori ravimite ohutusprofiilidega.
English: The medicine contains the active substance turoctocog alfa.
Estonian: Ravim sisaldab toimeainena alfaturoktokogi.
English: Patients with haemophilia A lack factor VIII, which prevents blood from clotting and can cause problems such as bleeding in the joints, muscles or internal organs.
Estonian: A-hemofiiliaga patsientidel on VIII hüübimisfaktori vaegus, mis takistab verd hüübimast ja põhjustab probleeme, näiteks verejookse liigestes, lihastes või siseelundites.
English: The active substance in NovoEight, turoctocog alfa, works in the same way as natural factor VIII and helps the blood to clot.
Estonian: NovoEighti toimeaine alfaturoktokog toimib samamoodi kui looduslik VIII hüübimisfaktor ning soodustab vere hüübimist.
English: What benefits of NovoEight have been shown in studies?
Estonian: Milles seisneb uuringute põhjal NovoEighti kasulikkus?
English: The Agency concluded that NovoEight is effective for treating and preventing bleeding episodes, with effects similar to other factor VIII products.
Estonian: Amet järeldas, et NovoEight on verejooksuepisoodide ravis ja ennetamisel efektiivne ning selle toime sarnaneb teiste VIII hüübimisfaktori ravimite toimega.
English: Some patients may develop factor VIII inhibitors, which can cause the medicine to stop working, resulting in a loss of bleeding control.
Estonian: Mõnel patsiendil võivad tekkida VIII hüübimisfaktori inhibiitorid, mis blokeerivad ravimi verejooksu tõkestava toime.
English: NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.
Estonian: NovoEight on ravim, mida kasutatakse verejooksude raviks ja ennetamiseks patsientidel, kellel on Ahemofiilia (VIII hüübimisfaktori vaegusest tingitud pärilik veritsushäire).
English: Why is NovoEight authorised?
Estonian: Miks NovoEight ELis heaks kiideti?
English: How does NovoEight work?
Estonian: Kuidas NovoEight toimib?
English: NovoEight can only be obtained with a prescription, and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia.
Estonian: Ravi tuleb alustada hemofiilia ravis kogenud arsti jälgimise all.
English: NovoEight is available for injection into a vein.
Estonian: NovoEighti turustatakse intravenoosse süstena.
English: An overview of NovoEight and why it is authorised in the EU
Estonian: Ülevaade ravimist NovoEight ja ELis müügiloa väljastamise põhjendus
English: NovoEight was effective at preventing and treating bleeding episodes in two main studies involving a total of 213 patients with haemophilia A. Neither study compared NovoEight with any other medicines.
Estonian: Kahes põhiuuringus, milles osales kokku 213 A-hemofiiliaga patsienti, oli NovoEight efektiivne verejooksuepisoodide ennetamisel ja ravis.
English: 3.1 mg / 24 h Transdermal patch Transdermal use sachet (coated paper/alu/LLDPE)
Estonian: Transdermaalne kotike (kattekihiga paber/alumiinium/LL DPE)
English: 1 patch
Estonian: 1 plaaster
English: This makes it hard to breathe.
Estonian: See raskendab hingamist.
English: This pack is not to be sold separately.
Estonian: Seda pakendit eraldi ei müüda.
English: or i.v.
Estonian: või i.v.
English: Date of first authorisation: 21 September 2009 Date of latest renewal: 26 May 2016
Estonian: Müügiloa esmase väljastamise kuupäev: 21. september 2009 Müügiloa viimase uuendamise kuupäev: 26. mai 2016
English: Avoid breathing through your nose.
Estonian: Vältige nina kaudu hingamist.
English: After identical single i.m.
Estonian: Pärast võrdseid ühekordseid i.m.
English: Other medicines and Cayston
Estonian: Muud ravimid ja Cayston
English: What if I need to stop my treatment before I've finished?
Estonian: Mida teha, kui ma pean ravi enne lõpetamist katkestama?
English: Use the prepared solution within 8 hours.
Estonian: Kasutage valmistatud lahus ära 8 tunni jooksul.
English: Solvent: 3 years.
Estonian: Lahusti: 3 aastat.
English: Overall, 539 patients (78% adults) were treated in these studies.
Estonian: Üldiselt sai nende uuringute raames ravi 539 patsienti (78% täiskasvanud).
English: All these may be signs of an allergic reaction.
Estonian: Need kõik võivad viidata allergilisele reaktsioonile.
English: The following pack sizes are available:
Estonian: Saadaval on järgmised pakendi suurused:
English: Powder vial: 4 years.
Estonian: Pulbriviaal: 4 aastat.
English: Adults and children 6 years and older
Estonian: Täiskasvanud ja 6-aastased ning vanemad lapsed
English: Currently available data are described in section 5.1 but no recommendation on posology can be given.
Estonian: Antud hetkel teadaolevad andmed on esitatud lõigus 5.1, aga soovitusi annustamise kohta ei ole võimalik anda.
English: This helps to ensure that you get the proper dose of medicine.
Estonian: See aitab tagada, et saaksite ravimi õige annuse.
English: The information that appears on the ampoule is presented below:
Estonian: Ampullil olev teave on toodud allpool:
English: Each treatment takes about 2 to 3 minutes to inhale.
Estonian: Iga ravi kestus peaks olema ligikaudu 2 kuni 3 minutit inhaleerimist.
English: Efficacy has not been established in patients with FEV1 > 75% predicted.
Estonian: Efektiivsust ei ole tõestatud patsientidel, kelle prognoositav FEV1 on >75%.
English: Microbiology
Estonian: Mikrobioloogia
English: However, all mean sputum concentration values were associated with relatively large standard deviations.
Estonian: Sellegipoolest seostati kõiki keskmise rögasisalduse väärtusi suhteliselt ulatuslike standardhälvetega.
English: If you get a rash, tell your doctor immediately because this could mean that you have an allergic reaction to Cayston.
Estonian: Kui teil tekib lööve, öelge seda kohe arstile, sest see võib tähendada, et teil on tekkinud Caystoni suhtes allergiline reaktsioon.
English: If a case of bronchospasm is suspected to be part of an allergic reaction appropriate measures should be taken (see “allergic reactions” paragraph above).
Estonian: Kui arvatakse, et bronhospasm on osa allergilisest reaktsioonist, tuleb kasutusele võtta sobivad meetmed (vt osa “Allergilised reaktsioonid” ülalt).
English: Begin your treatment.
Estonian: Ravi alustamine.
English: Recovery data indicate that about 10% of the dose is excreted as this metabolite.
Estonian: Taastusandmed näitavad, et umbes 10% annusest eritub selle metaboliidina.
English: If you notice that the performance has changed before this time (for instance, if it takes longer to produce a mist, more than 5 minutes), please refer to the Altera Nebuliser instructions for use.
Estonian: Kui märkate seadme tööomaduste muutumist juba varem (näiteks udu moodustamiseks kulub kauem aega, rohkem kui 5 minutit), lugege Altera nebulisaatori kasutusjuhendit.
English: The ampoule is imprinted in English only.
Estonian: Ampullile on trükitud ainult ingliskeelne teave.
English: bronchodilator mucolytics and lastly, Cayston.
Estonian: bronhodilataator mukolüütikum ja viimasena, Cayston.
English: Figure 3a
Estonian: Joonis 3a
English: Carefully remove (but do not yet discard) the rubber stopper.
Estonian: Eemaldage ettevaatlikult kummist punnkork (kuid ärge visake seda veel ära).
English: Refer to section 4.4.
Estonian: Vt lõik 4.4.
English: Do not twist the blue cap.
Estonian: Ärge väänake sinist korki.
English: When all of the medicine has been delivered, you will hear a tone that means “treatment complete” (2 beeps).
Estonian: Kui kogu ravim on manustatud, kuulete tooni, mis tähendab “ravi lõpetatud” (2 signaalheli).
English: The safety and efficacy of Cayston in children younger than 6 years of age have not been established.
Estonian: Caystoni ohutus ja efektiivsus lastel vanuses alla 6 aasta ei ole veel tõestatud.
English: Hold the handset level and place the mouthpiece in your mouth and close your lips around it (Figure 4).
Estonian: Hoidke käsinebulisaatorit horisontaalselt, pange huulik suhu ning sulgege huuled selle ümber (joonis 4).
English: - if you are allergic to aztreonam or any of the other ingredients of this medicine (listed in section 6).
Estonian: - kui olete astreonaami või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: - if you have ever had low lung function tests.
Estonian: - kui teil on kunagi esinenud kopsufunktsiooni näitajate halvenemist.
English: Use this medicine immediately after preparation.
Estonian: Kasutage seda ravimit kohe pärast lahustamist.
English: Cayston is not for use in children under the age of 6 years.
Estonian: Caystonit ei tohi kasutada lastel vanuses alla 6 eluaasta.
English: In healthy subjects 60-70% of a single i.m.
Estonian: Tervetel uuringus osalejatel väljus 60-70% ühekordsest i.m.
English: What Cayston looks like and contents of the pack
Estonian: Kuidas Cayston välja näeb ja pakendi sisu
English: The information that appears on the solvent ampoule is provided in English only (see section 6).
Estonian: Lahustiampullil olev teave on saadaval ainult inglise keeles (vt lõik 6).
English: If you have ever coughed up blood you should only use Cayston if your doctor thinks the benefit of taking this medicine outweighs the risk of coughing up blood.
Estonian: Kui olete kunagi verd köhinud, tohite Caystonit kasutada ainult juhul, kui teie arsti arvates kaalub selle ravimi kasutamisest saadav kasu üles veriköha riski.
English: Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Estonian: Järgida tuleb sobiva antibakteriaalse ravi ametlikke juhiseid.
English: Peak levels of aztreonam are achieved at about one hour after i.m.
Estonian: Astreonaami maksimaalne tase saavutatakse ligikaudu üks tund pärast i.m.
English: What Cayston is and what it is used for
Estonian: Mis ravim on Cayston ja milleks seda kasutatakse
English: Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1000 to < 1/100).
Estonian: Sagedus on määratletud järgmiselt: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10) ja aeg-ajalt